Ahmedabad-based Cadila Pharmaceuticalsintroduced the first novel product for cancer managementwhich it claims is a significant breakthrough in the treatment of lung cancer.
Mycidac-C is an innovative research product for patients suffering from a cancer sub-type - non-small cell lung cancer - and will be priced at Rs 4,000 for 10 injections. The total cost of therapy to patients is estimated at Rs 40,000 - which the company claims is affordable as cancer treatment is generally exorbitant.
Cadila CMD Dr Rajiv Modi said on Thursday, "Our drug is a significant breakthrough in the management of squamous non-small cell lung cancer (NSCLC), since the introduction of first line cancer drugs nearly 30 years ago."
As per World Health Organisation, approximately 1.25 million people are diagnosed with lung cancer every year worldwide.
Lung cancer kills more people than the three next commonest cancers combined. The drug has already been approved by the country's drug controller general.
According to Dr Modi, the drug is the world's first targeted active immunotherapy, and is to be used in conjunction with other cancer medication. Final trials on the drug suggest that it improves median survival by over 40% in patients suffering from squamous NSCLC.
"It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years," Modi said.
Mycidac-C is an innovative research product for patients suffering from a cancer sub-type - non-small cell lung cancer - and will be priced at Rs 4,000 for 10 injections. The total cost of therapy to patients is estimated at Rs 40,000 - which the company claims is affordable as cancer treatment is generally exorbitant.
Cadila CMD Dr Rajiv Modi said on Thursday, "Our drug is a significant breakthrough in the management of squamous non-small cell lung cancer (NSCLC), since the introduction of first line cancer drugs nearly 30 years ago."
As per World Health Organisation, approximately 1.25 million people are diagnosed with lung cancer every year worldwide.
Lung cancer kills more people than the three next commonest cancers combined. The drug has already been approved by the country's drug controller general.
According to Dr Modi, the drug is the world's first targeted active immunotherapy, and is to be used in conjunction with other cancer medication. Final trials on the drug suggest that it improves median survival by over 40% in patients suffering from squamous NSCLC.
"It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years," Modi said.
No comments:
Post a Comment